Literature DB >> 27714416

Serum total bilirubin levels and disease severity in patients with stable coronary artery disease.

J Yu1, J-L Han2, G-S Wang1, L-J Guo1, W Gao1.   

Abstract

AIM: Serum total bilirubin (STB), a protective cardiovascular factor, was retrospectively investigated to determine the relationship between STB levels and the severity of disease in Chinese patients with stable coronary artery disease (CAD). PATIENTS AND METHODS: A total of 347 eligible patients presenting to our department from December 2007 to December 2012 were divided into tertiles according to their Syntax scores (low, moderate, and high). To clarify the association between STB levels and major adverse cardiovascular events (MACE), all patients were divided into two groups according to the median baseline STB (greater than or less than 13.2 μmol/l), which was measured after at least 12-h fast. All participants were followed for a mean of 37.1 months for MACE, including all-cause death, recurrent nonfatal myocardial infarction, and recurrent percutaneous coronary intervention.
RESULTS: The STB levels were significantly lower in the high Syntax score group than those of the other groups and were negatively correlated with the Syntax score and number of diseased vessels. Follow-up data showed a higher incidence of MACE in the low STB group compared with the high STB group. Elevated STB levels predict the long-term prognosis of patients with stable angina pectoris. Finally, Kaplan-Meier analysis showed a significantly higher event-free survival rate in the patients with high STB levels than those in the low STB group.
CONCLUSIONS: STB levels were independently associated with the severity of disease in patients with stable CAD. Elevated STB is associated with cardiovascular events and may be useful as a biomarker of the severity and prognosis of stable CAD.

Entities:  

Keywords:  Major adverse cardiovascular event; Myocardial infarction; Percutaneous coronary intervention; Prognosis; Syntax scores

Mesh:

Substances:

Year:  2016        PMID: 27714416     DOI: 10.1007/s00059-016-4476-7

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  35 in total

1.  Relation between serum total bilirubin levels and severity of coronary artery disease in patients with non-ST-segment elevation myocardial infarction.

Authors:  Mehmet Gungor Kaya; Omer Sahin; Mahmut Akpek; Mustafa Duran; Onur Kadir Uysal; Serhat Karadavut; M Said Cosgun; Goktug Savas; Ahmet Oguz Baktir; Bahadir Sarli; Yat Yin Lam
Journal:  Angiology       Date:  2013-10-07       Impact factor: 3.619

2.  Usefulness of the SYNTAX score for predicting clinical outcome after percutaneous coronary intervention of unprotected left main coronary artery disease.

Authors:  Davide Capodanno; Maria Elena Di Salvo; Glauco Cincotta; Marco Miano; Claudia Tamburino; Corrado Tamburino
Journal:  Circ Cardiovasc Interv       Date:  2009-06-30       Impact factor: 6.546

3.  5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions.

Authors:  Patrick W Serruys; Yoshinobu Onuma; Scot Garg; Pascal Vranckx; Bernard De Bruyne; Marie-Claude Morice; Antonio Colombo; Carlos Macaya; Gert Richardt; Jean Fajadet; Christian Hamm; Monique Schuijer; Tessa Rademaker; Kristel Wittebols; Hans Peter Stoll
Journal:  J Am Coll Cardiol       Date:  2010-02-18       Impact factor: 24.094

4.  [Role of the SYNTAX score in assessing the outcomes of percutaneous interventions in patients with ST segment elevation myocardial infarction].

Authors:  R S Tarasov; V I Ganyukov; O L Barbarash; L S Barbarash
Journal:  Angiol Sosud Khir       Date:  2016

5.  The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase.

Authors:  R Tenhunen; H S Marver; R Schmid
Journal:  Proc Natl Acad Sci U S A       Date:  1968-10       Impact factor: 11.205

Review 6.  Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease.

Authors:  G Franceschini
Journal:  Am J Cardiol       Date:  2001-12-20       Impact factor: 2.778

7.  Antioxidant properties of conjugated bilirubin and biliverdin: biologically relevant scavenging of hypochlorous acid.

Authors:  R Stocker; E Peterhans
Journal:  Free Radic Res Commun       Date:  1989

8.  Association of serum total bilirubin level with severity of coronary atherosclerosis is linked to systemic inflammation.

Authors:  Mehmet Kadri Akboga; Ugur Canpolat; Asife Sahinarslan; Yakup Alsancak; Serdar Nurkoc; Dursun Aras; Sinan Aydogdu; Adnan Abaci
Journal:  Atherosclerosis       Date:  2015-03-02       Impact factor: 5.162

9.  Does Serum Bilirubin level on admission predict TIMI flow grade and in-hospital MACE in patients with STEMI undergoing primary PCI.

Authors:  Turgay Celik; Mehmet G Kaya; Mahmut Akpek; Mikail Yarlioglues; Bahadir Sarli; Ramazan Topsakal; Charles Michael Gibson
Journal:  Angiology       Date:  2013-01-31       Impact factor: 3.619

10.  Assessment of the SYNTAX score in the Syntax study.

Authors:  Patrick W Serruys; Yoshinobu Onuma; Scot Garg; Giovanna Sarno; Marcel van den Brand; Arie-Pieter Kappetein; Nic Van Dyck; Michael Mack; David Holmes; Ted Feldman; Marie-Claude Morice; Antonio Colombo; Eric Bass; Katrin Leadley; Keith D Dawkins; Gerrit-Anne van Es; Marie-Angèle M Morel; Friedrich W Mohr
Journal:  EuroIntervention       Date:  2009-05       Impact factor: 6.534

View more
  2 in total

1.  Association between Initial Serum Total Bilirubin and Clinical Outcome in Myocardial Infarction with Non-Obstructive Coronary Arteries.

Authors:  Guoqing Yin; Lu Liu; Abdul-Quddus Mohammed; Rong Jiang; Fuad A Abdu; Wenliang Che
Journal:  Int J Med Sci       Date:  2022-05-27       Impact factor: 3.642

2.  Prognostic Value of Serum Total Bilirubin after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome.

Authors:  Chengchun Tang; Hao Qian; Dong Wang; Yong Qiao; Gaoliang Yan
Journal:  Biomed Res Int       Date:  2019-05-28       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.